ECM
MYOV

Element Capital Management’s Myovant Sciences Ltd. MYOV Stock Holding History

Element Capital Management’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22,620
Closed -$265K – 110
2017
Q2 		$265K Buy
+22,620
New +$280K 0.05% 82

Other funds holding MYOV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Element Capital Management's MYOV Position: Q3 2017 in Review

Element Capital Management sold out of Myovant Sciences Ltd. (MYOV) in Q3 2017, closing a stake of 22,620 shares — an estimated $265K sold.

Element Capital Management first reported a position in MYOV in Q2 2017 and held it in 1 quarter. The position peaked at $265K in Q2 2017. 34 funds tracked by Wall St. Rank hold MYOV as of Q3 2017.

  • Element Capital Management reported no remaining Myovant Sciences Ltd. position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 22,620 Myovant Sciences Ltd. shares in Q3 2017, an estimated $265K.
  • Element Capital Management first reported a position in Myovant Sciences Ltd. in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's Myovant Sciences Ltd. position peaked at $265K in Q2 2017.
  • 34 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.